Biotech | April 03, 2022
Dr. Reddy's and MediCane Health launch medical cannabis in Germany
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
The launch of medical cannabis products resulted from an agreement between the two companies signed in 2021
First and only once-weekly patch for convenient, well-tolerated delivery of most used drug for the treatment of Alzheimer's-related dementia
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
Cysoni is a bionic device that paces the heart with real-time respiratory modulation. The innovation stems from the idea that heart rate increases and decreases with each breath in normal physiology, termed ‘respiratory sinus arrhythmia’ (RSA)
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
MultiTEP Platform-based vaccine targeting three B cell epitopes of pathological ?-Synuclein simultaneously shows protective efficacy in mouse model of synucleinopathies
Launching in 2022, its availability will be expanded to the global market
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Subscribe To Our Newsletter & Stay Updated
